Praxis Precision Medicines, Inc.
PRAX
Classement en actions
#2728
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the... Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Prix de l'action
$249.62
Capitalisation boursière
$6.97B
Changement (1 jour)
3.25%
Changement (1 an)
31.39%
Pays
US
Échange Praxis Precision Medicines, Inc. (PRAX)
Catégorie
Healthcare
EPS pour Praxis Precision Medicines, Inc. (PRAX)
EPS au June 2026 TTM : $-12.95
Selon les derniers rapports financiers et le cours de l'action de Praxis Precision Medicines, Inc., l’EPS actuel de la société (TTM) est de $-12.95. À la fin de 2023, la société avait un EPS de $-18.69 une diminution par rapport à celui de 2022, qui était de $-69.33.
Historique de l'EPS de Praxis Precision Medicines, Inc. de 2018 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-12.95 | 26.84% |
| 2024 | $-10.21 | -45.37% |
| 2023 | $-18.69 | -73.04% |
| 2022 | $-69.33 | 17.59% |
| 2021 | $-58.96 | -43.09% |
| 2020 | $-103.61 | -70.25% |
| 2019 | $-348.24 | 13.53% |
| 2018 | $-306.73 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -233.75% |
US
|
|
| $-7.98 | -38.38% |
US
|
|
| $-5.29 | -59.15% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -314.21% |
NL
|
